ARS Pharmaceuticals, Inc. — Director's Dealing 2024

Sep 19, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-09-18

Reporting Person: Karas Eric (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-09-18	Common Stock	M	10000	$1.50	Acquired	15693	Direct
2024-09-18	Common Stock	S	10000	$14	Disposed	5693	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-09-18	Stock Option (Right to Buy)	$1.50	M	10000	Disposed	2032-05-23	Common Stock (10000)	Direct

Footnotes

F1: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.

F2: Immediately exercisable.